SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • May 23rd, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 23rd, 2013 Company Industry JurisdictionTHIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Agreement”) is made and entered into as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the holders of Series C Preferred Stock (as defined below) listed on Exhibit A hereto (the “Series C Preferred Holders”), each of the holders of Series B Preferred Stock (as defined below) listed on Exhibit B hereto (the “Series B Preferred Holders”), each of the holders of Series A Preferred Stock (as defined below) listed on Exhibit C hereto (the “Series A Preferred Holders”), each of the holders of Series A-1 Preferred Stock (as defined below) listed on Exhibit D hereto (the “Series A-1 Preferred Holders” and, together with the Series B Preferred Holders and the Series A Preferred Holders, the “Preferred Holders”), each of the holders of Common Stock (as defined below) listed on Exhibit E hereto (the “Common Holders” and collectively with the Series A Preferred Holders and
SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • April 30th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 30th, 2013 Company Industry JurisdictionTHIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Agreement”) is made and entered into as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the holders of Series C Preferred Stock (as defined below) listed on Exhibit A hereto (the “Series C Preferred Holders”), each of the holders of Series B Preferred Stock (as defined below) listed on Exhibit B hereto (the “Series B Preferred Holders”), each of the holders of Series A Preferred Stock (as defined below) listed on Exhibit C hereto (the “Series A Preferred Holders”), each of the holders of Series A-1 Preferred Stock (as defined below) listed on Exhibit D hereto (the “Series A-1 Preferred Holders” and, together with the Series B Preferred Holders and the Series A Preferred Holders, the “Preferred Holders”), each of the holders of Common Stock (as defined below) listed on Exhibit E hereto (the “Common Holders” and collectively with the Series A Preferred Holders and
SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Delaware
Contract Type FiledMarch 20th, 2013 Company JurisdictionTHIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Agreement”) is made and entered into as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the holders of Series C Preferred Stock (as defined below) listed on Exhibit A hereto (the “Series C Preferred Holders”), each of the holders of Series B Preferred Stock (as defined below) listed on Exhibit B hereto (the “Series B Preferred Holders”), each of the holders of Series A Preferred Stock (as defined below) listed on Exhibit C hereto (the “Series A Preferred Holders”), each of the holders of Series A-1 Preferred Stock (as defined below) listed on Exhibit D hereto (the “Series A-1 Preferred Holders” and, together with the Series B Preferred Holders and the Series A Preferred Holders, the “Preferred Holders”), each of the holders of Common Stock (as defined below) listed on Exhibit E hereto (the “Common Holders” and collectively with the Series A Preferred Holders and